Insights into drug resistance of mutations D30N and I50V to HIV-1 protease inhibitor TMC-114: Free energy calculation and molecular dynamic simulation

The single mutations D30N and I50V are considered as the key residue mutations of the HIV-1 protease drug resistance to inhibitors in clinical use. In this work, molecular dynamics (MD) simulations combined with the molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) method have been performed to investigate the drug-resistant mechanisms of D30N and I50V to an inhibitor TMC-114. The analyses of absolute binding free energies using the separate trajectory approach suggests that the decrease in the van der Waals energy and electrostatic energy in the gas phase results in the drug resistance of D30N to TMC-114, while for I50V, the decrease in the electrostatic energy mainly drive its drug resistance to TMC-114. Detailed binding free energies between TMC-114 and individual protein residues are computed by using a per-residue basis decomposition method, which provides insights into the inhibitor-protein binding mechanism and also explains the drug-resistant mechanisms of mutations D30N and I50V to TMC-114. The study shows that the loss of the hydrogen bond between TMC-114 and the side chain of Asn30′ is the main driving force of the resistance of D30N to TMC-114, and in the case of I50V, the increase in the polar solvation energies between TMC-114 and two residues Val50′ and Asp30′ definitively drives the resistance of I50V to TMC-114. We expect that this work can provide some helpful insights into the nature of mutational effect and aid the future design of better inhibitors.

[1]  M. Sanner,et al.  Reduced surface: an efficient way to compute molecular surfaces. , 1996, Biopolymers.

[2]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[3]  Renxiao Wang,et al.  A computational analysis of the binding affinities of FKBP12 inhibitors using the MM‐PB/SA method , 2006, Proteins.

[4]  Thomas D. Wu,et al.  Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments , 2003, Journal of Virology.

[5]  E. Freire,et al.  Adaptive inhibitors of the HIV-1 protease. , 2005, Progress in biophysics and molecular biology.

[6]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[7]  J. Mestan,et al.  New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. , 1998, Journal of medicinal chemistry.

[8]  Dirk Lamoen,et al.  Conformational Analysis of TMC114, a Novel HIV-1 Protease Inhibitor , 2008, J. Chem. Inf. Model..

[9]  Arun K. Ghosh,et al.  Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. , 2006, Journal of medicinal chemistry.

[10]  S. Vasavanonda,et al.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Brendan A. Larder,et al.  Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples , 2000, AIDS.

[12]  P A Kollman,et al.  Continuum solvent studies of the stability of RNA hairpin loops and helices. , 1998, Journal of biomolecular structure & dynamics.

[13]  I B Duncan,et al.  Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.

[14]  T. Meek,et al.  Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. , 1991, Biochemistry.

[15]  John Z H Zhang,et al.  Selectivity of neutral/weakly basic P1 group inhibitors of thrombin and trypsin by a molecular dynamics study. , 2008, Chemistry.

[16]  Ye Mei,et al.  Quantum and Molecular Dynamics Study for Binding of Macrocyclic Inhibitors to Human α-Thrombin , 2007 .

[17]  D. Faulds,et al.  Nelfinavir. A review of its therapeutic efficacy in HIV infection. , 1998, Drugs.

[18]  P. Darke,et al.  L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Cheng Luo,et al.  Molecular insight into the interaction between IFABP and PA by using MM-PBSA and alanine scanning methods. , 2007, The journal of physical chemistry. B.

[20]  P A Kollman,et al.  Molecular dynamics and continuum solvent studies of the stability of polyG-polyC and polyA-polyT DNA duplexes in solution. , 1998, Journal of biomolecular structure & dynamics.

[21]  M. Navia,et al.  Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.

[22]  Jung-Hsin Lin,et al.  Restrained molecular dynamics simulations of HIV‐1 protease: The first step in validating a new target for drug design , 2006, Biopolymers.

[23]  M. Lepšík,et al.  Efficiency of a second‐generation HIV‐1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations , 2004, Proteins.

[24]  D. Case,et al.  Modification of the Generalized Born Model Suitable for Macromolecules , 2000 .

[25]  Bentley Strockbine,et al.  Binding of antifusion peptides with HIVgp41 from molecular dynamics simulations: Quantitative correlation with experiment , 2007, Proteins.

[26]  D. Case,et al.  Characterization of domain-peptide interaction interface: a case study on the amphiphysin-1 SH3 domain. , 2008, Journal of molecular biology.

[27]  Dale J. Kempf,et al.  ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease , 1998, Antimicrobial Agents and Chemotherapy.

[28]  D. Case,et al.  Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. , 2003, Journal of molecular biology.

[29]  P. Kollman,et al.  How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? , 2000 .

[30]  C. Flexner.  HIV-protease inhibitors. , 1998, The New England journal of medicine.

[31]  William A. McLaughlin,et al.  Evaluating the potency of HIV‐1 protease drugs to combat resistance , 2008, Proteins.

[32]  Tingjun Hou,et al.  Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance. , 2007, Journal of medicinal chemistry.

[33]  G. Moyle.  Overcoming obstacles to the success of protease inhibitors in highly active antiretroviral therapy regimens. , 2002, AIDS patient care and STDs.

[34]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[35]  Irene T Weber,et al.  High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. , 2004, Journal of molecular biology.

[36]  P. Kollman,et al.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.